E-Cigarettes, the FDA, Public Health, and Harm Reduction: A Response to the Open Peer Commentaries

American Journal of Bioethics 23 (1):1-4 (2022)
  Copy   BIBTEX

Abstract

We appreciate that all our commentators accepted the central framework we argued for, namely that the FDA has multiple roles and attendant responsibilities, and we are excited to see this framework...

Links

PhilArchive



    Upload a copy of this work     Papers currently archived: 92,100

External links

Setup an account with your affiliations in order to access resources via your University's proxy server

Through your library

Similar books and articles

Harm Reduction: A Misnomer.Nicholas B. King - 2020 - Health Care Analysis 28 (4):324-334.
Disgust or Dignity? The Moral Basis of Harm Reduction.Natalie Stoljar - 2020 - Health Care Analysis 28 (4):343-351.
Toward a Philosophy of Harm Reduction.Shannon Dea - 2020 - Health Care Analysis 28 (4):302-313.
Kantian Harm Reduction.Sarah Hoffman - 2020 - Health Care Analysis 28 (4):335-342.
Complicity in Harm Reduction.Timothy Kirschenheiter & John Corvino - 2020 - Health Care Analysis 28 (4):352-361.

Analytics

Added to PP
2022-10-27

Downloads
19 (#801,562)

6 months
12 (#216,527)

Historical graph of downloads
How can I increase my downloads?

Author Profiles

Larisa Svirsky
University of Toronto, St. George Campus
Dana Howard
Ohio State University

Citations of this work

No citations found.

Add more citations

References found in this work

Advice on Vaping in the Face of Empirical and Ethical Uncertainty.Kalle Grill - 2022 - American Journal of Bioethics 22 (10):20-22.
Moral Wrongs, Epistemic Wrongs, and the FDA.Jack Harris - 2022 - American Journal of Bioethics 22 (10):34-37.
Limitations on the Capability of the FDA to Advise.Aaron S. Kesselheim & Leah Z. Rand - 2022 - American Journal of Bioethics 22 (10):15-17.

View all 8 references / Add more references